Caveolin-1 deficiency may predispose african americans to systemic sclerosis-related interstitial lung disease

Arthritis and Rheumatology

Volumn 66, Issue 7, 2014, Pages 1909-1919

  Reese, Charles ^a   Perry, Beth ^a   Heywood, Jonathan ^a   Bonner, Michael ^a   Visconti, Richard P ^a   Lee, Rebecca ^a   Hatfield, Corey M ^a   Silver, Richard M ^a   Hoffman, Stanley ^a   Tourkina, Elena ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CHEMOKINE RECEPTOR CXCR4; FIBRONECTIN; STROMAL CELL DERIVED FACTOR 1;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CELL DIFFERENTIATION; CELL MIGRATION; CYTOSKELETON; HEALTH DISPARITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

AFRICAN AMERICANS; CAVEOLIN 1; CELL DIFFERENTIATION; CELL MOVEMENT; CYTOSKELETON; EUROPEAN CONTINENTAL ANCESTRY GROUP; FIBROBLASTS; HUMANS; LUNG DISEASES, INTERSTITIAL; MAP KINASE SIGNALING SYSTEM; MONOCYTES; RECEPTORS, CXCR4; RISK FACTORS; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903442145     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38572     Document Type: Article

References (44)

1. Atamas SP, White B,. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003; 14: 537-50.
2. Altman RD, Medsger TA Jr, Bloch DA, Michel BA,. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991; 34: 403-13.
3. Silver RM,. Interstitial lung disease of systemic sclerosis. Int Rev Immunol 1995; 12: 281-91.
4. Mayes MD,. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54.
5. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-55. et al.
6. Steen VD, Conte C, Owens GR, Medsger TA Jr., Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-9.
7. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 40: 734-42.
8. Krishnan E, Furst DE,. Systemic sclerosis mortality in the United States: 1979-1998. Eur J Epidemiol 2005; 20: 855-61.
9. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, et al. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 318-26.
10. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM,. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006; 33: 263-8.
11. Beall AD, Nietert PJ, Taylor MH, Mitchell HC, Shaftman SR, Silver RM, et al. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol 2007; 34: 1277-82.
12. Silver RM, Bogatkevich G, Tourkina E, Nietert PJ, Hoffman S,. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol 2012; 24: 642-8.
13. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, et al. Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis Rheum 2007; 56: 3468-77.
14. August P, Suthanthiran M,. Transforming growth factor β and progression of renal disease. Kidney Int Suppl 2003; 87: S99-104.
15. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP,. Identification of peptide and protein ligands for the caveolin-scaffolding domain: implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 1997; 272: 6525-33.
16. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, et al. Caveolin interaction with protein kinase C: isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 1997; 272: 33416-21.
17. Rybin VO, Xu X, Steinberg SF,. Activated protein kinase C isoforms target to cardiomyocyte caveolae: stimulation of local protein phosphorylation. Circ Res 1999; 84: 980-8.
18. Tourkina E, Gooz P, Pannu J, Bonner M, Scholz D, Hacker S, et al. Opposing effects of protein kinase Cα and protein kinase C on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem 2005; 280: 13879-87.
19. Wang XM, Zhang Y, Kim HP, Zhou Z, Feghali-Bostwick CA, Liu F, et al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 2006; 203: 2895-906.
20. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP, Lisanti MP,. Caveolin-1 regulates transforming growth factor (TGF)-β/SMAD signaling through an interaction with the TGF-β type I receptor. J Biol Chem 2001; 276: 6727-38.
21. Le Saux CJ, Teeters K, Miyasato SK, Hoffmann PR, Bollt O, Douet V, et al. Down-regulation of caveolin-1, an inhibitor of transforming growth factor-β signaling, in acute allergen-induced airway remodeling. J Biol Chem 2008; 283: 5760-8.
22. Yan SR, Fumagalli L, Berton G,. Activation of SRC family kinases in human neutrophils: evidence that p58C-FGR and p53/56LYN redistributed to a Triton X-100-insoluble cytoskeletal fraction, also enriched in the caveolar protein caveolin, display an enhanced kinase activity. FEBS Lett 1996; 380: 198-203.
23. Uhal BD,. Apoptosis in lung fibrosis and repair. Chest 2002; 122: 293S-8S.
24. Trojanowska M,. Noncanonical transforming growth factor β signaling in scleroderma fibrosis. Curr Opin Rheumatol 2009; 21: 623-9.
25. Del Galdo F, Lisanti MP, Jimenez SA,. Caveolin-1, transforming growth factor-β receptor internalization, and the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2008; 20: 713-9.
26. Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL,. Distinct endocytic pathways regulate TGF-β receptor signalling and turnover. Nat Cell Biol 2003; 5: 410-21.
27. Del Galdo F, Sotgia F, de Almeida CJ, Jasmin JF, Musick M, Lisanti MP, et al. Decreased expression of caveolin-1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 2008; 58: 2854-65.
28. Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, Harley R, et al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 2008; 294: L843-61.
29. Tourkina E, Richard M, Oates J, Hofbauer A, Bonner M, Gooz P, et al. Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis 2010; 69: 1220-6.
30. Kasper M, Reimann T, Hempel U, Wenzel KW, Bierhaus A, Schuh D, et al. Loss of caveolin expression in type I pneumocytes as an indicator of subcellular alterations during lung fibrogenesis. Histochem Cell Biol 1998; 109: 41-8.
31. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001; 293: 2449-52.
32. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001; 276: 38121-38.
33. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 2000; 6: 1362-7.
34. Bernatchez PN, Bauer PM, Yu J, Prendergast JS, He P, Sessa WC,. Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides. Proc Natl Acad Sci U S A 2005; 102: 761-6.
35. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
36. LeRoy EC, Black C, Fleishmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5. et al.
37. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, et al. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011; 4: 15.
38. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B,. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009; 86: 1111-8.
39. Mehrad B, Burdick MD, Zisman DA, Keane MP, Belperio JA, Strieter RM,. Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun 2007; 353: 104-8.
40. Mehrad B, Burdick MD, Strieter RM,. Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol 2009; 41: 1708-18.
41. Nietert PJ, Silver RM,. Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol 2003; 30: 1238-43.
42. Nietert PJ, Silver RM, Mitchell HC, Shaftman SR, Tilley BC,. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005; 32: 1888-92.
43. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA Jr., A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum 2012; 64: 2986-94.
44. Bains SN, Tourkina E, Atkinson C, Joseph K, Tholanikunnel B, Chu HW, et al. Loss of caveolin-1 from bronchial epithelial cells and monocytes in human subjects with asthma. Allergy 2012; 67: 1601-4.